JPWO2020102096A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020102096A5 JPWO2020102096A5 JP2021525223A JP2021525223A JPWO2020102096A5 JP WO2020102096 A5 JPWO2020102096 A5 JP WO2020102096A5 JP 2021525223 A JP2021525223 A JP 2021525223A JP 2021525223 A JP2021525223 A JP 2021525223A JP WO2020102096 A5 JPWO2020102096 A5 JP WO2020102096A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- optionally
- hydroxy
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 705
- 150000001875 compounds Chemical class 0.000 claims description 358
- 125000003118 aryl group Chemical group 0.000 claims description 336
- 125000005843 halogen group Chemical group 0.000 claims description 268
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 229
- -1 S(O 2 )NR 11 R 12 Chemical group 0.000 claims description 229
- 125000003545 alkoxy group Chemical group 0.000 claims description 220
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 201
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 201
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 195
- 125000004043 oxo group Chemical group O=* 0.000 claims description 177
- 125000001424 substituent group Chemical group 0.000 claims description 116
- 125000004429 atoms Chemical group 0.000 claims description 110
- 125000005842 heteroatoms Chemical group 0.000 claims description 95
- 125000000623 heterocyclic group Chemical group 0.000 claims description 91
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 88
- 229910052799 carbon Inorganic materials 0.000 claims description 80
- 125000001153 fluoro group Chemical group F* 0.000 claims description 58
- 229910052760 oxygen Inorganic materials 0.000 claims description 57
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 54
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 53
- 229910052717 sulfur Inorganic materials 0.000 claims description 53
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 49
- 125000002950 monocyclic group Chemical group 0.000 claims description 49
- 201000010099 disease Diseases 0.000 claims description 46
- 125000002619 bicyclic group Chemical group 0.000 claims description 45
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 claims description 44
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 43
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 41
- 125000002837 carbocyclic group Chemical group 0.000 claims description 36
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 27
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- 239000011780 sodium chloride Substances 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 229910052757 nitrogen Chemical group 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 17
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 150000001204 N-oxides Chemical class 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 claims description 15
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims description 15
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 15
- VMWJCFLUSKZZDX-UHFFFAOYSA-N N,N-dimethylmethanamine Chemical group [CH2]N(C)C VMWJCFLUSKZZDX-UHFFFAOYSA-N 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 13
- 125000001544 thienyl group Chemical group 0.000 claims description 13
- 125000002947 alkylene group Chemical group 0.000 claims description 11
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 11
- 125000005418 aryl aryl group Chemical group 0.000 claims description 9
- 125000004076 pyridyl group Chemical group 0.000 claims description 9
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims description 9
- 230000003042 antagnostic Effects 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 239000011593 sulfur Chemical group 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 7
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 6
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims description 6
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 6
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims description 6
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 5
- 229920000089 Cyclic olefin copolymer Polymers 0.000 claims description 5
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims description 5
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims description 5
- 125000004104 aryloxy group Chemical group 0.000 claims description 5
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 206010059245 Angiopathy Diseases 0.000 claims description 4
- 206010003816 Autoimmune disease Diseases 0.000 claims description 4
- 208000003432 Bone Disease Diseases 0.000 claims description 4
- 210000003169 Central Nervous System Anatomy 0.000 claims description 4
- 208000009745 Eye Disease Diseases 0.000 claims description 4
- 201000005099 Langerhans-cell histiocytosis Diseases 0.000 claims description 4
- 208000009856 Lung Disease Diseases 0.000 claims description 4
- 208000008466 Metabolic Disease Diseases 0.000 claims description 4
- 206010048592 Musculoskeletal disease Diseases 0.000 claims description 4
- 206010033616 Pancreatic disease Diseases 0.000 claims description 4
- 208000006641 Skin Disease Diseases 0.000 claims description 4
- 206010047461 Viral infection Diseases 0.000 claims description 4
- 208000001756 Virus Disease Diseases 0.000 claims description 4
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims description 4
- 201000009673 liver disease Diseases 0.000 claims description 4
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 230000017613 viral reproduction Effects 0.000 claims description 4
- 125000006587 (C5-C10) heteroarylene group Chemical group 0.000 claims description 3
- 206010017758 Gastric cancer Diseases 0.000 claims description 3
- 208000007906 Intestinal Disease Diseases 0.000 claims description 3
- 206010024324 Leukaemias Diseases 0.000 claims description 3
- 206010029151 Nephropathy Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010038428 Renal disease Diseases 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 3
- 201000009251 multiple myeloma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
- 206010001897 Alzheimer's disease Diseases 0.000 claims description 2
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000006673 Asthma Diseases 0.000 claims description 2
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010011401 Crohn's disease Diseases 0.000 claims description 2
- 208000007465 Giant Cell Arteritis Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 206010019799 Hepatitis viral Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000002780 Macular Degeneration Diseases 0.000 claims description 2
- 206010027476 Metastasis Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000002865 Osteopetrosis Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 2
- 206010033649 Pancreatitis chronic Diseases 0.000 claims description 2
- 206010061536 Parkinson's disease Diseases 0.000 claims description 2
- 206010061481 Renal injury Diseases 0.000 claims description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims description 2
- 206010043207 Temporal arteritis Diseases 0.000 claims description 2
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims description 2
- 201000003229 acute pancreatitis Diseases 0.000 claims description 2
- 201000001320 atherosclerosis Diseases 0.000 claims description 2
- 230000001684 chronic Effects 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 201000005569 gout Diseases 0.000 claims description 2
- 201000004044 liver cirrhosis Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 230000002018 overexpression Effects 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 201000004681 psoriasis Diseases 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 201000010874 syndrome Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 201000006704 ulcerative colitis Diseases 0.000 claims description 2
- 201000001862 viral hepatitis Diseases 0.000 claims description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 230000002685 pulmonary Effects 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 description 88
- 125000000304 alkynyl group Chemical group 0.000 description 52
- 125000003342 alkenyl group Chemical group 0.000 description 42
- 125000004438 haloalkoxy group Chemical group 0.000 description 42
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 description 19
- 125000002393 azetidinyl group Chemical group 0.000 description 18
- 125000003566 oxetanyl group Chemical group 0.000 description 18
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 13
- 150000002431 hydrogen Chemical class 0.000 description 11
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 9
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 5
- HWYHDWGGACRVEH-UHFFFAOYSA-N N-methyl-N-(4-pyrrolidin-1-ylbut-2-ynyl)acetamide Chemical group CC(=O)N(C)CC#CCN1CCCC1 HWYHDWGGACRVEH-UHFFFAOYSA-N 0.000 description 4
- 150000002829 nitrogen Chemical group 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 3
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 3
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- 125000004430 oxygen atoms Chemical group O* 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 201000004304 Addison's disease Diseases 0.000 description 1
- 208000001083 Kidney Disease Diseases 0.000 description 1
- 206010034695 Pernicious anaemia Diseases 0.000 description 1
- 206010038436 Renal failure acute Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 200000000010 kidney injury Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024091521A JP2024113083A (ja) | 2018-11-13 | 2024-06-05 | Ｎｌｒｐ活性に関連する病態を治療するための化合物及び組成物 |
Applications Claiming Priority (27)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862760209P | 2018-11-13 | 2018-11-13 | |
| US201862760244P | 2018-11-13 | 2018-11-13 | |
| US201862760248P | 2018-11-13 | 2018-11-13 | |
| US62/760,209 | 2018-11-13 | ||
| US62/760,248 | 2018-11-13 | ||
| US62/760,244 | 2018-11-13 | ||
| US201862768811P | 2018-11-16 | 2018-11-16 | |
| US62/768,811 | 2018-11-16 | ||
| US201862769151P | 2018-11-19 | 2018-11-19 | |
| US201862769165P | 2018-11-19 | 2018-11-19 | |
| US62/769,151 | 2018-11-19 | ||
| US62/769,165 | 2018-11-19 | ||
| US201962795919P | 2019-01-23 | 2019-01-23 | |
| US62/795,919 | 2019-01-23 | ||
| US201962796361P | 2019-01-24 | 2019-01-24 | |
| US201962796356P | 2019-01-24 | 2019-01-24 | |
| US62/796,356 | 2019-01-24 | ||
| US62/796,361 | 2019-01-24 | ||
| US201962836585P | 2019-04-19 | 2019-04-19 | |
| US201962836575P | 2019-04-19 | 2019-04-19 | |
| US201962836577P | 2019-04-19 | 2019-04-19 | |
| US62/836,585 | 2019-04-19 | ||
| US62/836,577 | 2019-04-19 | ||
| US62/836,575 | 2019-04-19 | ||
| US201962895595P | 2019-09-04 | 2019-09-04 | |
| US62/895,595 | 2019-09-04 | ||
| PCT/US2019/060770 WO2020102096A1 (en) | 2018-11-13 | 2019-11-11 | Compounds and compositions for treating conditions associated with nlrp activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024091521A Division JP2024113083A (ja) | 2018-11-13 | 2024-06-05 | Ｎｌｒｐ活性に関連する病態を治療するための化合物及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022507065A JP2022507065A (ja) | 2022-01-18 |
| JPWO2020102096A5 true JPWO2020102096A5 (ru) | 2022-11-22 |
Family
ID=68841175
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525223A Pending JP2022507065A (ja) | 2018-11-13 | 2019-11-11 | Ｎｌｒｐ活性に関連する病態を治療するための化合物及び組成物 |
| JP2024091521A Pending JP2024113083A (ja) | 2018-11-13 | 2024-06-05 | Ｎｌｒｐ活性に関連する病態を治療するための化合物及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024091521A Pending JP2024113083A (ja) | 2018-11-13 | 2024-06-05 | Ｎｌｒｐ活性に関連する病態を治療するための化合物及び組成物 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20230031406A1 (ru) |
| EP (1) | EP3880660A1 (ru) |
| JP (2) | JP2022507065A (ru) |
| KR (1) | KR20210096123A (ru) |
| CN (1) | CN113166065A (ru) |
| AU (1) | AU2019379109B2 (ru) |
| BR (1) | BR112021008969A2 (ru) |
| CA (1) | CA3114918A1 (ru) |
| CL (1) | CL2021001228A1 (ru) |
| CO (1) | CO2021006075A2 (ru) |
| CR (1) | CR20210235A (ru) |
| EC (2) | ECSP21033236A (ru) |
| IL (1) | IL283042B1 (ru) |
| JO (1) | JOP20210105A1 (ru) |
| MA (1) | MA54229A (ru) |
| MX (1) | MX2021005529A (ru) |
| PE (1) | PE20211698A1 (ru) |
| SG (1) | SG11202103405TA (ru) |
| TW (1) | TW202031647A (ru) |
| WO (1) | WO2020102096A1 (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11370776B2 (en) * | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| AU2018317798A1 (en) | 2017-08-15 | 2020-02-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| EP3707134A1 (en) | 2017-11-09 | 2020-09-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| MX2022005732A (es) | 2019-11-12 | 2022-06-09 | Chengdu Baiyu Pharmaceutical Co Ltd | Derivado de amida y metodo de preparacion para el mismo y uso del mismo en medicina. |
| CR20220356A (es) * | 2020-01-22 | 2022-08-30 | Hoffmann La Roche | Compuestos de sulfonimidamida como moduladores de nlrp3 |
| WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| CN116917282A (zh) * | 2021-05-10 | 2023-10-20 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
| CN116635373A (zh) * | 2021-05-10 | 2023-08-22 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
| CN114989058B (zh) * | 2022-06-02 | 2024-04-16 | 中国科学院成都生物研究所 | 一种手性氯代砜亚胺类化合物及其衍生物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3259253T2 (ro) * | 2015-02-16 | 2020-06-30 | Univ Queensland | Sulfoniluree și compuși înrudiți și utilizări ale acestora |
| MA44729A (fr) * | 2016-04-18 | 2021-05-12 | Novartis Ag | Composés et compositions pour traiter des états associés à une activité de nlrp |
| AU2018307743C1 (en) * | 2017-07-24 | 2021-09-09 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| US11370763B2 (en) * | 2017-07-24 | 2022-06-28 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
-
2019
- 2019-11-11 MA MA054229A patent/MA54229A/fr unknown
- 2019-11-11 SG SG11202103405TA patent/SG11202103405TA/en unknown
- 2019-11-11 PE PE2021000700A patent/PE20211698A1/es unknown
- 2019-11-11 JP JP2021525223A patent/JP2022507065A/ja active Pending
- 2019-11-11 KR KR1020217017180A patent/KR20210096123A/ko unknown
- 2019-11-11 IL IL283042A patent/IL283042B1/en unknown
- 2019-11-11 CA CA3114918A patent/CA3114918A1/en active Pending
- 2019-11-11 WO PCT/US2019/060770 patent/WO2020102096A1/en active Application Filing
- 2019-11-11 EP EP19817831.1A patent/EP3880660A1/en active Pending
- 2019-11-11 CR CR20210235A patent/CR20210235A/es unknown
- 2019-11-11 JO JOP/2021/0105A patent/JOP20210105A1/ar unknown
- 2019-11-11 CN CN201980074397.XA patent/CN113166065A/zh active Pending
- 2019-11-11 AU AU2019379109A patent/AU2019379109B2/en active Active
- 2019-11-11 US US17/292,881 patent/US20230031406A1/en active Pending
- 2019-11-11 MX MX2021005529A patent/MX2021005529A/es unknown
- 2019-11-11 BR BR112021008969-1A patent/BR112021008969A2/pt unknown
- 2019-11-13 TW TW108141175A patent/TW202031647A/zh unknown
-
2021
- 2021-05-10 CO CONC2021/0006075A patent/CO2021006075A2/es unknown
- 2021-05-11 CL CL2021001228A patent/CL2021001228A1/es unknown
- 2021-05-11 EC ECSENADI202133236A patent/ECSP21033236A/es unknown
-
2024
- 2024-06-05 JP JP2024091521A patent/JP2024113083A/ja active Pending
- 2024-06-07 EC ECSENADI202444340A patent/ECSP24044340A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528889A5 (ru) | ||
| JP2020537657A5 (ru) | ||
| JP2019515952A5 (ru) | ||
| JP2019518071A5 (ru) | ||
| US11234977B2 (en) | Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals | |
| JP7367169B2 (ja) | Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法 | |
| JP7016809B2 (ja) | 抗ウイルス剤としての四環式ピリドン化合物 | |
| EP1838320B1 (en) | Cxcr4 antagonists for the treatment of medical disorders | |
| JPWO2020102096A5 (ru) | ||
| WO2017216686A1 (en) | 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals | |
| JP6858984B2 (ja) | がんおよび糖尿病の治療に有用な６−ヘテロシクリル−４−モルホリン−４−イルピリジン−２−オン化合物 | |
| EA032509B1 (ru) | Замещенные индазолы, способы их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств | |
| RU2008141368A (ru) | Новые гетероциклические соединения замещенного пиридина с антагонистической активностью схсr3 | |
| US20090124636A1 (en) | Chemical compounds | |
| CN105189453A (zh) | 氨磺酰基-芳基酰胺及其作为用于乙型肝炎治疗的药物的用途 | |
| CN105683201B (zh) | 新的含n‑杂环碳烯配体的金(iii)络合物、合成及其在癌症治疗和硫醇检测中的应用 | |
| CN105601573A (zh) | 2-氨基嘧啶类化合物及其药物组合物和应用 | |
| CA2575777A1 (en) | Compositions and methods for treatment of colitis using methimazole and/or cyclic thione derivatives | |
| RU2014121074A (ru) | Соединения 8-фторфталазин-1(2н)-она в качестве ингибиторов тирозинкиназы брутона | |
| JP7201260B2 (ja) | ピリジンアミン－ピリドンおよびピリミジンアミン－ピリドン化合物 | |
| US20170073337A1 (en) | Dihydrothiazine and dihydrooxazine derivatives having bace1 inhibitory activity | |
| JPWO2020086732A5 (ru) | ||
| ES2839523T3 (es) | Derivado de quinazolinona, procedimiento de preparación del mismo, composición farmacéutica y aplicaciones | |
| CN112707905B (zh) | 一种三并杂环化合物及其制备方法和用途 | |
| JP2021501756A5 (ru) |